ALPHATOPICS
SEMINAR

11th Symposium on Herbal Medicinal Products in Europe 2022 with Satellite Symposium on Medicinal Cannabis

5th – 6th October 2022
Bonn – Universitätsclub

Hybrid event

INTRODUCTION

11th Symposium on Herbal Medicinal Products in Europe

We kindly invite you to the symposium on herbal medicines.

With our annual symposium, we address current topics and place particular emphasis on the dialogue between stakeholders and authorities. In addition, the symposium is established as a networking event.

For the first time, we will not focus on the DACH region in terms of content and will extend the topics to a European context.

Accordingly, the symposium will be held in English. This year, the symposium will also take place the day before **with a satellite event on medicinal cannabis**.

Is it not possible for you to come to Bonn in person? Then we invite you to join us online. The event will again be **held in a hybrid format** – so you can conveniently follow the presentations via the live stream.

We are also happy to offer you and your team attractive special prices for groups. Please contact us.

ALPHATOPICS SYMPOSIUM **2022**

Satellite Symposium on Medicinal Cannabis

Medicinal cannabis and cannabis-based products have been available in EU member states as single-patient prescriptions without regular marketing authorisations for a couple of years.

The Netherlands was the first member state to allow this, and since then, other member states have followed. Besides the Netherlands, Germany is currently the most important market for such products. However, the regulatory framework for the approval of medicinal cannabis and its distribution to patients in the distinct EU member states is not at all harmonised, and there are distinct national regulations.

Regarding the quality of such products, the general requirements for herbal medicinal products as defined in the European Pharmacopoeia, national pharmacopoeias and the EMA guidance documents in place alongside GMP requirements in the EU are applicable. However, for a couple of aspects, every EU member state follows its own interpretation of these requirements. With the satellite symposium, we aim to provide an overview of the current requirements in the EU and distinct member states and to enable communication between stakeholders regarding current developments and how to achieve greater harmonisation.

ALPHATOPICS
SEMINAR

SCHEDULE OF LECTURES

DAY 1 / Wednesday, 5th October 2022

Satellite symposium on medicinal cannabis

TIME	TOPIC	FACILITATOR
08:30	Welcome & registration	
09:00 – 09:45	**Examples of different medicinal cannabis products and respective regulatory frameworks in EU member states**	Dr. Malgorzata Meunier, Panaxia Pharmaceutical Industries Ltd.
09:45 – 10:30	**Regulations on medicinal cannabis in Switzerland**	Dr. Martin Ziak*, Swissmedic
10:30 – 11:00	Coffee break	
11:00 – 11:45	**The Danish pilot programme for medicinal cannabis: Quality requirements – so far**	Kristine Hvolby*, Danish Medicines Agency
11:45 – 12:30	**Extemporaneous medicinal cannabis preparations in Germany (framework – experiences – problems)**	Dr. Andreas Ziegler, ZIENCE – Exchange of ideas
12:30 – 13:30	Lunch	
13:30 – 14:15	**Quality requirements for medicinal cannabis products in Europe**	Dr. Markus Veit, Alphatopics
14:15 – 14:45	**The German Cannabis Agency – federal institution, pharmaceutical company and wholesaler**	Cindy Ledderhose*, Federal Institute for Drugs and Medical Devices, Bonn
14:45 – 15:00	Coffee break	
15:00 – 15:45	**Classification, GMP requirements and supply chain for medicinal cannabis products**	Dr. Reinhard Kerker, GMP Inspector, RP Tübingen
15:45 – 16:30	**Regulatory challenges of low-THC cannabis products** (novel foods, flavors, cosmetics, medicinal products, smoked and vaped products)	Dr. Dirk Lachenmeier*, CVUA Karlsruhe
16:30 – 17:15	**Round table**	
17:15 – 19:30	Get-together for all the Day 1 and Day 2 participants	

NETWORKING: Time for collegial discussions and networking with drinks & finger food. The Day 2 symposium participants are also cordially invited to join.

ALPHATOPICS SYMPOSIUM **2022**

SCHEDULE OF LECTURES

DAY 2 / Thursday, 6th October 2022

Main symposium

TIME	TOPIC	FACILITATOR
	Plenary lecture	
09:00 – 09:45	**What comes after the monographs – The work of the HMPC in the future**	Dr. Emiel van Galen*, Chair HMPC, CBG-MEB
09:45 – 10:30	**Herbal medicinal products in Switzerland – A look back and to the future on the occasion of the 20th anniversary of Swissmedic**	Dr. Martin Ziak*, Swissmedic
10:30 – 11:00	Coffee break	
11:00 – 11:45	**Herbal medicinal products and respective starting materials in the European Pharmacopoeia – A retrospective and outlook**	Dr. Ulrich Rose, formerly EDQM
11:45 – 12:30	**Quality requirements for herbal substances, preparations and medicinal products: Has the optimum been achieved?**	Dr. Reinhard Länger*, BASG
12:30 – 13:30	Lunch	
13:30 – 14:15	**Revised HMPC/QWP quality and specification guidelines for herbal medicinal products in Europe**	Dr. Markus Veit, Alphatopics
14:15 – 14:45	Coffee break	
14:45 – 15:30	**Experiences and success factors for the registration of well-established herbal medicinal products in non-EU markets**	Dr. Bernd Röther, Bionorica SE
15:30 – 16:15	**Regulatory update contaminants** (nitrosamines, metal impurities, estragole, pesticides in herbal medicinal products)	Dr. Nicole Armbrüster, BPI
16:15 – 17:00	**Round table**	

* Please be aware that all the speakers have agreed to participate; however, speakers from competent authorities may still be awaiting internal approval for their participation.

SPEAKERS

Dr. Nicole Armbrüster is a PhD biologist and has many years of experience in the field of plant ecology and plant cultivation in southern Africa. After several years of working for a consultancy firm with a strong focus on regulatory consulting of natural health products, she is now Head of Biological and Herbal Medicinal Products at the German Pharmaceutical Industry Association in Berlin.

Kristine Hvolby* studied pharmacy at the University of Copenhagen. She is employed as a special adviser in the Danish Medicines Agency, and has almost 25 years of experience as a quality assessor. Her main focus is the quality of (traditional) herbal medicinal products and medicinal cannabis, but also the evaluation of the quality of medicinal products containing chemical active substances. She is an agency representative in the Danish Pharmacopoeia Commission, Pharmacognosy Subcommittee, and she has been a member of the Quality Drafting Group (QDG) of the EMA Committee on Herbal Medicinal Products (HMPC) since 2005.

Dr. Reinhard Kerker studied pharmacy and economics. He received his doctorate in pharmaceutical technology from the University of Munich. For 25 years he has been working in the pharmaceutical industry in manufacturing, pharmaceutical development, quality control, and as plant manager and managing director. Since 2016 he has been a GMP inspector at the medicines control center Baden-Württemberg. He has experience from more than a dozen inspections of medical cannabis producers.

Dr. Dirk Lachenmeier* works as a food chemist and toxicologist in official food control at the Chemical and Veterinary Investigation Agency in Karlsruhe. He is an expert in the field of plant-based foods, with a focus on NMR analysis and the product areas of cannabis and coffee. He has authored over 400 publications and has contributed to various working groups in the field of risk assessment and food safety, including WHO IARC, DIN, GDCh, and DFG Senate Commission on Food Safety.

Univ.-Doz. Dr. Reinhard Länger* studied pharmacy and habilitated at the university of Vienna. Main research topic was the quality control of herbal drugs. Since 2006 he is assessor at the Austrian Agency for Health and Food Sefatey (AGES)/ Austrian Federal Office for Safety in Health Care (BASG) and is head of the department for herbal, homoeopathic and veterinary medicinal products at, Austrian delegate to HMPC (EMA, Amsterdam), expert in the Working groups on Herbal Extracts and on TCM of EDQM and lecturer at the University of Vienna.

Cindy Ledderhose* has been a scientist at the German Cannabis Agency of the Federal Institute for Drugs and Medical Devices (BfArM) in Bonn since 2021, where she is the Responsible Person for Wholesale. Between 2010 and 2020 she held different positions in the pharmaceutical industry – e.g. galenic development; Head of Unit Stability Investigations; in-vitro diagnostic research and development. After obtaining her Bachelor of Engineering, Pharmaceutical Technology in 2008 and her Master of Science, Pharmaceutical Biotechnology in 2011, she received her approbation as a pharmacist in 2018.

Dr. Malgorzata Meunier, Deputy General Manager for Europe at Panaxia Pharmaceuticals Ltd., is responsible for the global business expansion and regulatory & innovation strategy of Panaxia's pharmaceutical products based on medical cannabis. She has been working in international pharmaceutical companies in France and Switzerland for the past 18 years, acting as R&D Lead and Principal Scientist in GSK Consumer Healthcare, Sunstar, Vifor Pharma, OM Pharma. She is an expert in the pharmaceutical development of drug products in various galenic formats (liquids, semi-liquids and solids). Dr. Malgorzata Meunier was born and raised in Poland, lived and studied in France, and worked and gained professional experience in Switzerland and Israel. She holds a PhD in Pharmaceutical Sciences from the Faculty of Pharmacy, University of Strasbourg (France), as well as a Master's degree from the Ecole Centrale de Lyon (France) and an Interuniversity Diploma in Medical Cannabis, from the Faculty of Medicine Paris Saclay in cooperation with the University of Montpellier.

ALPHATOPICS SYMPOSIUM **2022**

Dr. Ulrich Rose is pharmacist by training and obtained his PhD in pharmaceutical chemistry in 1985. Before joining the EDQM in 1991 he was assistant professor and lecturer for pharmaceutical analysis and physicochemistry at the University of Mainz in Germany. Until 2011 he was responsible for the establishment and monitoring of Ph. Eur. reference standards in the European Pharmacopoeia laboratory. Moreover, he was involved in the elaboration and revision of Ph. Eur. monographs. After that he became coordinator and auditor for EDQM's Mutual Joint Audit programme. Within this function he audited the Official Medicines Control Laboratories in and sometimes outside Europe. Since 2014 he has been Head of Division A and Deputy Head of the European Pharmacopoeia Department, where he has been overlooking the monograph work on chemically defined substances, herbals, medicinal products and general chapters and has been involved in the international harmonisation of pharmacopoeias.

Dr. Bernd Röther is trained as a chemist and obtained his doctorate in organic chemistry at the Justus-Liebig-University of Gießen. He has 25 years of experience in drug regulatory affairs and has managed the division at BIONORICA SE since 2008. He has a profound knowledge of international DRA requirements and keeps close contact with the health authorities in Europe and abroad. Furthermore he is a lecturer at the Friedrich-Wilhelm University of Bonn in the Study Course 'Master of Drug Regulatory Affairs', Module 4. He is participating in the expert groups on phytotherapy of the associations BPI (Chairman) and the BAH. At the same time, he is board member in the Society for Medicinal Plants and Natural Products Research (GA).

Dr. Emiel van Galen* is Head of Department for Herbal Medicines and Novel Foods at the Agency of the Medicines Evaluation Board in Utrecht. Since March 2020 he has been Chair of the Committee on Herbal Medicinal Products, which after two years of virtual meetings, has recently resumed its meetings on the EMA premises in Amsterdam. A good moment to resume personal meetings with outside parties as well.

Prof. Dr. Markus Veit is the Managing Director of ALPHATOPICS GmbH. He studied pharmacy in Frankfurt, obtained his doctorate at the Julius-Maximilians-University in Würzburg and habilitated there. He is a pharmacist with special training and experience in pharmaceutical analysis and validation. He is a member of the German pharmacopeial expert committee at BfArM. In the past 25 years, he has worked as a managing director in companies providing services for the pharmaceutical industry with a focus on pharmaceutical development, testing and regulatory affairs. At the same time, he has designed and led numerous training and continuing education events for employees in the pharmaceutical and medical device industry.

Dr. Martin Ziak* is the Head of the Division Complementary and Herbal Medicines at Swissmedic in Bern. He studied biochemistry at the University of Zurich and obtained his PhD in 1991. For more than 15 years he worked as a research group leader in basic medical research at the University Hospital in Zurich. He was also a lecturer at the Faculty of Medicine of the University of Zurich. Since 2009, he has been occupying various leading functions in the sector "marketing authorisation" at Swissmedic. Presently, he also represents Switzerland at the International Regulatory Cooperation for Herbal Medicines (IRCH) and is a member of the Steering Committee.

Dr. Andreas S. Ziegler has been a specialist pharmacist for pharmaceutical technology since 2007 and holds the lectureship for pharmaceutical technology at the Friedrich-Alexander University of Erlangen-Nuremberg. He studied pharmacy there, followed by a doctorate at the university's Chair of Pharmaceutical Technology and Biopharmacy. Since 2005, he has been a speaker and science journalist with a focus on life science and science communication. For many years he has been dealing intensively with the legal and pharmaceutical questions related to the processing of medicinal cannabis in pharmacies and is one of the leading experts in this field.

Satellite symposium on medicinal cannabis

Examples of different medicinal cannabis products and respective regulatory frameworks in EU member states

09:00 – 09:45

Dr. Malgorzata Meunier, Panaxia Pharmaceutical Industries Ltd.

After a long period of prohibition, European health institutions have understood the need to regulate patient access to medical cannabis. However, due to regulatory differences in the perception of "what is medical cannabis", Europe still does not facilitate the pathway to obtain finished pharmaceutical products registered under MA.

The aim of this presentation is to provide an overview of the regulations in the main European countries where medical cannabis products are commercially available. Magistral preparations as a means to provide patients with access to medical cannabis (in Germany and Poland) will also be discussed.

Regulations on medicinal cannabis in Switzerland

09:45 – 10:30

Dr. Martin Ziak*, Swissmedic

The Swiss Parliament approved a revision of the Narcotics Act on 19th March 2021. The revised Narcotics Act and the revised ordinances are expected to enter into force in autumn 2022. The consequences for the marketing authorisation of medicinal products containing the active substance "cannabis" will be discussed.

The Danish pilot programme for medicinal cannabis: Quality requirements – so far

11:00 – 11:45

Kristine Hvolby*, Danish Medicines Agency

A Danish pilot programme for medicinal cannabis products was initiated in 2018. Since then, it has been possible to obtain a license to grow cannabis plants in Denmark, in order to use the attained herbal drug in medicinal cannabis products. Export of medicinal cannabis is also allowed. Alternatively, cannabis products from other countries can be imported to Denmark. The pilot programme was renewed in January 2022.

The products are exempted from a marketing authorisation. However, detailed requirements are set for product quality, product information, and manufacturing licenses ensuring compliance with GACP and GMP. The field is constantly evolving at a national and international level; both the Applicants and the Agency are gradually gaining more and more experience, trying to navigate with limited harmonization within the EU.

The presentation will focus on regulatory challenges related to the quality requirements for the products.

E.g.: What kind of active ingredients are allowed? Can homogeneity be ensured? Is it acceptable to decarboxylate cannabis? To irradiate? How should the products be declared? How to deal with stability? What quality requirements should be set for imported products?

ALPHATOPICS SYMPOSIUM 2022

CONTENT OF LECTURES

DAY 1 / Wednesday, 5th October 2022

Satellite symposium on medicinal cannabis

Extemporaneous medicinal cannabis preparations in Germany (framework – experiences – problems)

11:45 – 12:30

Dr. Andreas Ziegler, ZIENCE – Exchange of ideas

The processing of cannabis and cannabinoids in compounded preparations is a particular challenge for pharmacies, since the relevant manufacturing techniques are very specific and hardly ever occur in other compounded preparations. At the same time, this special kind of pharmaceuticals and its specific implications are largely unknown for many companies, as they are often familiar with the processes of industrial production, but not with drug preparation in pharmacies, for which special legal regulations apply. However, considering that in 2021 78 % of all cannabis prescriptions dispensed in Germany were compounded preparations, the importance of this type of medicinal preparation is enormous for the cannabis sector.

In order to contribute to a better understanding of this special drug class, the most important aspects of the legal framework will be presented in this lecture. Common problems arising in everyday work for both parties – pharmacies and industry – will also be discussed, as well as conclusions that can be drawn from 5 years of experience with cannabis in compounding.

Quality requirements for medicinal cannabis products in Europe

13:30 – 14:15

Dr. Markus Veit, Alphatopics

Regarding the quality of medicinal cannabis (flowers, preparations, medicinal products), the general requirements for herbal medicinal products as defined in the European Pharmacopoeia, national pharmacopoeias and the EMA guidance documents in place beside GMP requirements in the EU are applicable. However, for a couple of aspects every EU member state follows its own interpretation of these requirements. To facilitate the free distribution of such products between EU member states in future and to harmonise requirements for quality and GMP, an EU-wide approach is needed. In the presentation the most important requirements and areas of conflict will be discussed.

The German Cannabis Agency – federal institution, pharmaceutical company and wholesaler

14:15 – 14:45

Cindy Ledderhose*, Federal Institute for Drugs and Medical Devices, Bonn

Following a change in policy, a new regulatory framework for medicinal cannabis came into force in Germany in 2017. In line with the provisions of the Single Convention on Narcotic Drugs, the German Cannabis Agency was established to direct and control the cultivation, production and distribution of medicinal canabis grown in Germany. Meanwhile, medicinal cannabis cultivated in Germany by three different contract partners of BfArM is distributed and available to patients with individual prescriptions. It is a particular experience to act as pharmaceutical company and wholesaler within the structure of a federal institution.

CONTENT OF LECTURES

DAY 1 / Wednesday, 5th October 2022

Satellite symposium on medicinal cannabis

Classification, GMP requirements and supply chain for medicinal cannabis products

15:00 – 15:45

Dr. Reinhard Kerker,
GMP Inspector,
RP Tübingen

What is the correct classification of medical cannabis products? Starting material, active ingredient, bulk drug or finished medicinal product, nothing like that or maybe all of them? The authorities and inspectorates outside the continent, in European countries and the German federal states could have different views.

Based on this, there are different requirements: GACP, GMP Part I or II, marketing authorisations; written confirmation or third-country inspection. Which sales channels and supply chains are established in the German market? Are there any court cases and changes based on them? What developments may be expected in Germany?

Within the scope of the lecture, an attempt will be made to answer these questions and further questions from the participants from a pharmacist's and GMP inspector's point of view.

Regulatory challenges of low-THC cannabis products

15:45 – 16:30

Dr. Dirk Lachenmeier*,
CVUA Karlsruhe

According to EMCDDA, the increase in the open sale of cannabis products in Europe has raised questions around the possible legal and commercial status of these products. The products are marketed for their low THC (tetrahydrocannabinol) content, which sellers claim exempt them from control by narcotics laws, or as sources of CBD (cannabidiol). On the other hand, legal forms of low-THC cannabis products include medicinal products available on prescription in pharmacies. However, most products for oral consumption are marketed OTC as food supplement, cosmetic, food flavour or even non-food, such as room fragrances or animal feeds, mostly to circumvent legal requirements, such as mandatory novel food approvals. Another group of products increasingly found on the market are low-THC variants intended for smoking (CBD-flowers) or vaping (CBD-containing liquids).

Apart from the general question on the legality of sale to the end consumer, the product group raises questions regarding safety, as some products may exceed toxicological thresholds for THC, such as the acute reference dose (ARfD) or even the lowest obeserved adverse effect level (LOAEL). Concerns about possible toxicity of chronic CBD exposure have also been raised.

This presentation will provide current examples from the practice of an official control laboratory with reference to the most recent court cases on low-THC cannabis and CBD in the area of lifestyle consumer products.

CONTENT OF LECTURES

DAY 2 / Thursday, 6th October 2022

Main symposium

What comes after the monographs – The work of the HMPC in the future

09:00 – 09:45

Dr. Emiel van Galen*,
Chair HMPC, CBG-MEB

Despite the somewhat acquiescent title 'What comes after the monographs?' we will shortly look back on what the HMPC has achieved the past years, and look ahead to see how the Committee stands at the doorstep of new challenges.

Herbal medicinal products in Switzerland – A look back and to the future on the occasion of the 20th anniversary of Swissmedic

09:45 – 10:30

Dr. Martin Ziak*,
Swissmedic

This year, 2022, Swissmedic can celebrate its 20th anniversary. The Swiss Therapeutic Products Act entered into force on 1st January 2002, thus laying the basis for an independent Swiss therapeutic products authority. The focus has always been, and still is, on the quality, safety and efficacy of therapeutic products in Switzerland. Innovation is advancing rapidly and Swissmedic is required to keep up with the latest developments. However, the anniversary year also provides an opportunity to look back on developments in the field of complementary and herbal medicinal products. On the other hand, it is an invitation to take a courageous look into the future.

Herbal medicinal products and respective starting materials in the European Pharmacopoeia – A retrospective and outlook

11:00 – 11:45

Dr. Ulrich Rose,
formerly EDQM

The European Pharmacopoeia (Ph. Eur.) lays down common quality standards for the manufacture and control of medicines in Europe and beyond. These quality standards – currently more than 2500 monographs and more than 370 general texts – cover active pharmaceutical ingredients, excipients, herbals, biologicals in their original state and in the form of pharmaceutical preparations and are legally binding for the 39 signatory parties to the Council of Europe's Convention on the elaboration of a European Pharmacopoeia.

In the field of herbal drugs and preparations, there are currently six general monographs, like on herbal drugs, herbal drug extracts or essential oils, 27 general texts, like pesticide residues, heavy metals in herbal drugs, HPTLC of herbal drugs and preparations and more than 320 individual monographs.

The monographs are elaborated similarly to monographs on chemically defined APIs or biologicals, and contain sections on definition, characters, identification, tests and assay.

In recent times particular interest was attributed to the elaboration of general chapter 2.8.26, which describes the control of contaminant pyrrolizidine alkaloids in herbals. Furthermore, the replacement of classical physico-chemical assays, like photometry or HPLC, by semi-quantitative HPTLC in TCM drugs has been accepted as an alternative by the Ph. Eur. Commission. Further interesting and challenging projects, like monographs on cannabis, are in progress.

Main symposium

Quality requirements for herbal substances, preparations and medicinal products: Has the optimum been achieved?

11:45 – 12:30

Dr. Reinhard Länger*, BASG

The system for quality control of herbal medicinal products appears to be clear: The European Pharmacopeia defines the quality criteria for a huge number of herbal substances and certain extracts. Additionally general classifications and requirements are provided. The HMPC elaborates guidance on the entire control strategy and the required documentation in the dossier. Both, Ph. Eur. and HMPC, make reference to each other, applicants apparently know what kind of data are required for acceptance of an application. However, when a closer look is taken on the required quality documentation from field to medicinal product, inconsistencies and space for improvement are evident.

The presentation will provide some examples and intends to initiate an open-minded discussion.

Revised HMPC/QWP quality and specification guidelines for herbal medicinal products in Europe

13:30 – 14:15

Dr. Markus Veit, Alphatopics

The two central guidelines of the EMA and the HMPC addressing specifications and all quality aspects of herbal medicinal products and the corresponding herbal starting materials and herbal preparations used as API have been fundamentally revised over the last three years and adapted to the current state of science and technology. The final versions were published in May. With the revision, several requirements that were previously addressed in question-and-answer papers and reflection papers were integrated into the guidelines.

In the presentation the most important aspects of this revision will be addressed.

Experiences and success factors for the registration of well-established herbal medicinal products in non-EU markets

14:45 – 15:30

Dr. Bernd Röther, Bionorica SE

In this talk emphasis will be put on the regions Eastern Europe, South Africa, Asia and North/South America with respect to the acceptance of European data to prove pharmaceutical quality, safety and efficacy of (traditional) herbal medicinal products.

Is a well-established medicinal use of a product in the European Union in any way being acknowledged by the competent health authorities in these regions? Do they have a common understanding on traditional use and if so, does this facilitate the registration process?

ALPHATOPICS SYMPOSIUM 2022

CONTENT OF LECTURES

DAY 2 / Thursday, 6th October 2022

Main symposium

Regulatory update contaminants

15:30 – 16:15

Dr. Nicole Armbrüster, BPI

Testing for contaminants in herbal raw materials and preparations plays an important role in the manufacture of safe herbal medicinal products. There are numerous official requirements, both at a national and European level, which are intended to reduce the risk of contamination with undesirable and toxic substances to a minimum.

This lecture will give an overview of the legal framework for compliance with the specifications for contaminants and impurities with regard to herbal substances and their preparations. In recent years, the possible contamination with undesirable substances has posed great challenges to manufacturers of herbal medicinal products. The current developments regarding the debates about limit values of toxic substances (e.g. nitrosamines, estragole, polycyclic hydrocarbons) in the manufacture of herbal medicinal products will be presented.

* Please be aware that all the speakers have agreed to participate; however, speakers from competent authorities may still be awaiting internal approval for their participation.

EVENT LOCATION

University Club in Bonn
The clubhouse, located in the beautiful park of the former Oberbergamt, is today a "centre for scientific and human encounters". Only a stone's throw away from the university and the Rhine. It's the ideal setting for our annual symposium.

Universitätsclub Bonn
Verein zur Förderung der wissenschaftlichen Kommunikation an der Universität Bonn e.V.
Konviktstraße 9
53113 Bonn
Germany

NETWORKING

5th October 17:00
Time for collegial discussions and networking with drinks & finger food. The Day 2 symposium participants are also cordially invited to join. It will also be possible to register for the next day.

HYBRID EVENT

Is it not possible for you to come to Bonn in person? Then we invite you to join us live online, as the event will take place in a hybrid format.

ALPHATOPICS SYMPOSIUM **2022**

HYBRID REGISTRATION

Participation fee

€1,690.00 per person plus VAT for both days

€950.00 per person plus VAT for a single day

The fee for face-to-face participation includes a buffet lunch and snacks, as well as drinks during the event and breaks. All participants will receive the conference documents as printable PDF documents on a USB drive.

www.alphatopics.de

With online participation, you can watch all presentations via the live stream and interact with us by chat. You will receive a personalised access code, a certificate of participation and the conference documents as printable PDF documents for download.

10% discount: For simultaneous registration of several persons from a single company. We are also happy to offer you and your team attractive special prices for groups. Please contact us.

Team discount

CONTACT

Mrs. Daniela Müller and Mrs. Birte Doering will be happy to assist you with your booking and are available to answer any further questions you may have.

Alphatopics office hours:
Monday to Thursday from 8:00 to 13:00

Phone: +49 8191 9737-130

ALPHATOPICS GmbH
Iglinger Straße 27
86916 Kaufering/Germany
info@alphatopics.de
www.alphatopics.de

ALPHATOPICS
SEMINAR